@misc{Antoszczyk_Sławomir_Ribozymes_2003,
 author={Antoszczyk, Sławomir and Nawrot, Barbara},
 volume={61},
 number={2},
 copyright={Creative Commons Attribution BY-SA 4.0 license},
 journal={Biotechnologia, vol.61, 2 (2003)-.},
 howpublished={online},
 year={2003},
 publisher={Committee on Biotechnology PAS},
 publisher={Institute of Bioorganic Chemistry PAS},
 language={pol},
 abstract={Catalytic nucleic acids, ribozymes and deoxyribozymes can act as efficientribonucleases and degrade target RNA molecules by complementary Watson-Crick base pairing and catalytic cleavage of their phosphodiesterinternucleotide bonds. This ability makes ribozymes and deoxyribozymes potent molecular tools for therapeutic applications. Recent achievements inribozymes design and technology enable the preparation of ribozymes whichcan be efficiently expressed in cellular systems, co-localize with the targetmRNA and exhibit high intracellular activity. Several examples of preclinical andclinical trials of ribozymes directed toward viral genes (HBV, HCV, HIV-1) andoncogenes are discussed in this review.},
 title={Ribozymes in medicine},
 type={Text},
 URL={http://rcin.org.pl/ichb/Content/135641/PDF/POZN271_170581_biotechnologia-2003-no2-antoszczyk.pdf},
 keywords={biotechnology},
}